CMS published a finalized update to its national coverage determination for transcatheter aortic valve replacement, adopting language that closely follows the wording of the June proposal. Stifel analysts characterized the final determination as constructive for the broader TAVR market and singled out Edwards Lifesciences for potential benefit because of the company’s market-leading position.
Stifel indicated that TAVR represents a global market exceeding $7 billion and accounts for roughly 75% of Edwards’ revenues, while representing about 5.5% of Medtronic’s revenues, per the firm’s estimates.
Concurrently, CMS said it will open a national coverage analysis focused on TAVR devices that treat aortic regurgitation. That review will include devices such as Edwards’ clinical-stage J-Valve as well as the privately held, FDA-approved JenaValve. CMS set an expected completion date for that analysis of June 8, 2027.
The final decision reaffirmed CMS’ earlier proposal to support use of TAVR in patients with asymptomatic aortic stenosis. Stifel described this outcome as both expected and favorable for the procedure, noting that expansion to asymptomatic patients was a principal reason for reopening the national coverage determination.
CMS retained the requirement for a multidisciplinary heart team to participate in aortic stenosis patient evaluation. The final document explicitly confirms the cardiac surgeon’s ongoing role, stating that the heart team process should include input from both cardiac surgery and interventional cardiology.
On patient assessment procedures, the finalized determination permits asynchronous review of medical records to help determine suitability for TAVR or alternative treatments. However, CMS maintained that patients must still receive an in-person evaluation and that the cardiac surgeon remains part of the care pathway. Stifel judged the overall update to be a net positive for TAVR.
One operational change finalized by CMS is that only a single TAVR operator is required to be present in the operating room during a procedure. CMS also reiterated that TAVR must be performed at sites with cardiac surgery back-up. Stifel highlighted the removal of a requirement to have a surgeon physically present in the room as a notable scheduling efficiency gain for TAVR programs.
Volume standards from the proposal were preserved in the final determination. The document stipulates that operators must perform 20 or more total transcatheter cardiac valve procedures, at least 15 of which must be TAVR, each year; alternatively, operators may meet a two-year threshold of 40 or more total procedures, with at least 30 being TAVR.
Medicare also removed the coverage with evidence development requirement for all severe aortic stenosis patients, except for the subgroup of newly covered asymptomatic severe aortic stenosis patients.
Stifel concluded that the CMS update supports Edwards Lifesciences’ long-range plan for revenue growth of more than 10%, and aligns with the company’s pipeline developments and favorable competitive dynamics.